<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03218800</url>
  </required_header>
  <id_info>
    <org_study_id>Ertapsubcut</org_study_id>
    <nct_id>NCT03218800</nct_id>
  </id_info>
  <brief_title>Ertapenem Administered Subcutaneously Versus Intravenously</brief_title>
  <official_title>Ertapenem Administered Subcutaneously Versus Intravenously for Urinary Tract Infections in Oncological Palliative Care Patients: a Randomized, Open, Non-inferiority Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Cancer, Brazil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Nacional de Cancer, Brazil</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Infections requiring intravenous antimicrobial therapy are very common events in patients
      with advanced cancer. Nevertheless, these patients frequently present vascular damages
      becoming extremely difficult to access and maintain intravenous route for hydration and
      nutritional support. In this context, the subcutaneous route could be implemented as an
      alternative route for replacement of fluids, electrolytes and drugs. Few studies have
      evaluated the possibility of using the subcutaneous route for treatment of infections though.

      Patients in palliative care often have infections caused by multidrug resistant bacterial
      such as beta-lactamase producing bacteria. In this context, we hypothesize Ertapenem
      subcutaneously is not inferior to the same drug intravenously for the treatment of urinary
      infections in patients on oncologic palliative care. A non-inferiority clinical trial would
      be adequate and could provide stronger evidence on the possibility of this alternative route
      for antibiotic therapy in urinary tract infections, with important advantages such as greater
      convenience of use.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized open label clinical trial to evaluate Ertapenem administered
      subcutaneously is non-inferior to the same antibiotic intravenously to treat urinary tract
      infections in oncological palliative care patients.

      The study will be performed at the Palliative Care Unit (PCU) of the National Cancer
      Institute of Brazil José Alencar Gomes da Silva (INCA), a 56-bed hospital and the only public
      hospital for cancer palliative care located in the city of Rio de Janeiro, Brazil.

      A sample of 82 patients was estimated, considering the level of significance (alpha) of
      unilateral 2.5%, the power of the study (1-beta) of 80%, the non-inferiority limit of 4%, and
      success percentages in the groups control and experimental studies of 92% and 100%,
      respectively. Once the high mortality rate of the study site (about 60%, according to
      unpublished administrative information), it was decided to increase this number by 30% to
      compensate for possible losses, totaling 106 patients, 53 in each arm.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>microbiological cure</measure>
    <time_frame>seven days for cystitis and fourteen days for pyelonephritis</time_frame>
    <description>negative uroculture at the end of the treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>30 days</time_frame>
    <description>infusion related adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical response</measure>
    <time_frame>14 days</time_frame>
    <description>improve urinary tract symptoms after ertapenem treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">106</enrollment>
  <condition>Urinary Tract Infections</condition>
  <arm_group>
    <arm_group_label>Intravenous Ertapenem</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with urinary tract infection will be treated with ertapenem by the intravenous route.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subcutaneous Ertapenem</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with urinary tract infection will be treated with ertapenem by the subcutaneous route.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Ertapenem</intervention_name>
    <description>Dose: 1g per day if creatinine clearance &gt; 30mL/min or 500 mg per day if creatinine clearance &lt; 30mL/min.
Dilution: 50 ml saline solution. Duration 30 minutes.</description>
    <arm_group_label>Intravenous Ertapenem</arm_group_label>
    <arm_group_label>Subcutaneous Ertapenem</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any type of cancer in palliative care;

          -  Urinary tract infection;

          -  Informed consent assigned by the patient or legal representative.

        Exclusion Criteria:

          -  Neutropenia;

          -  Unconsciousness.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luciana Ramadas</last_name>
    <role>Study Chair</role>
    <affiliation>INCA- Instituto Nacional de Câncer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luciana Ramadas, MD</last_name>
    <phone>552132073924</phone>
    <email>luramadas@yahoo.com.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>INCA Instituto Nacional do Cancer</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20560-120</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luciana Ramadas</last_name>
    </contact>
    <investigator>
      <last_name>Luciana Ramadas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <link>
    <url>https://www.merck.com/product/usa/pi_circulars/i/invanz/invanz_pi.pdf</url>
    <description>ertapenem prescribing information</description>
  </link>
  <link>
    <url>https://www.sealedenvelope.com/power/binary-noninferior/</url>
    <description>Power calculator for binary outcome non-inferiority trial</description>
  </link>
  <reference>
    <citation>Forestier E, Gros S, Peynaud D, Levast M, Boisseau D, Ferry-Blanco C, Labe A, Lecomte C, Rogeaux O. [Ertapenem administered intravenously or subcutaneously for urinary tract infections caused by ESBL producing enterobacteriacea]. Med Mal Infect. 2012 Sep;42(9):440-3. doi: 10.1016/j.medmal.2012.07.005. Epub 2012 Aug 25. French.</citation>
    <PMID>22925551</PMID>
  </reference>
  <reference>
    <citation>Frasca D, Marchand S, Petitpas F, Dahyot-Fizelier C, Couet W, Mimoz O. Pharmacokinetics of ertapenem following intravenous and subcutaneous infusions in patients. Antimicrob Agents Chemother. 2010 Feb;54(2):924-6. doi: 10.1128/AAC.00836-09. Epub 2009 Nov 23.</citation>
    <PMID>19933804</PMID>
  </reference>
  <reference>
    <citation>Grigoryan L, Trautner BW, Gupta K. Diagnosis and management of urinary tract infections in the outpatient setting: a review. JAMA. 2014 Oct 22-29;312(16):1677-84. doi: 10.1001/jama.2014.12842. Review.</citation>
    <PMID>25335150</PMID>
  </reference>
  <reference>
    <citation>Piaggio G, Elbourne DR, Pocock SJ, Evans SJ, Altman DG; CONSORT Group. Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. JAMA. 2012 Dec 26;308(24):2594-604. doi: 10.1001/jama.2012.87802.</citation>
    <PMID>23268518</PMID>
  </reference>
  <reference>
    <citation>Tomera KM, Burdmann EA, Reyna OG, Jiang Q, Wimmer WM, Woods GL, Gesser RM; Protocol 014 Study Group. Ertapenem versus ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults: results of a prospective, randomized, double-blind multicenter study. Antimicrob Agents Chemother. 2002 Sep;46(9):2895-900.</citation>
    <PMID>12183244</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2017</study_first_submitted>
  <study_first_submitted_qc>July 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2017</study_first_posted>
  <last_update_submitted>July 14, 2017</last_update_submitted>
  <last_update_submitted_qc>July 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Nacional de Cancer, Brazil</investigator_affiliation>
    <investigator_full_name>Luciana Ramadas</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>subcutaneous</keyword>
  <keyword>ertapenem</keyword>
  <keyword>urinary tract infection</keyword>
  <keyword>advanced cancer</keyword>
  <keyword>palliative care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ertapenem</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

